Arrakis Therapeutics to Participate in Upcoming May Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small molecule medicines that directly target RNA, today announced that company management will participate in the following upcoming investor conferences:

2022 RBC Capital Markets Global Healthcare Conference
Michael Gilman, Ph.D., Chief Executive Officer of Arrakis, will participate in a fireside chat on Tuesday, May 17, 2022 at 10:30 a.m. ET in New York. Company management will also participate in one-on-one meetings.

UBS Global Healthcare Conference 2022
Company management will participate in one-on-one meetings on Monday, May 23, 2022 in New York.

About Arrakis Therapeutics

Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. Arrakis is building a proprietary pipeline of RNA-targeted small molecule (rSM) medicines focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on LinkedIn.